Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winquist

Showing results (91-100 of 234) with videos related to

Pageof 24
Sort By:
Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.
Journal of Oncology Practice|September 4, 2012
Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agentsMatthew A Weir, Tara Gomes, Eric Winquist, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 27, 2008
Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysisScott C Morgan, Tricia S Waldron, Libni Eapen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 10, 2010
High-intensity focused ultrasound for prostate cancer: a practice guidelineHimu Lukka, Tricia Waldron, Joseph Chin, et al.
Journal of Medical Imaging and Radiation Oncology|October 15, 2013
Can radiological changes in lymph node volume during treatment predict success of radiation therapy in patients with locally advanced head and neck squamous cell carcinoma?Sanju Mishra, Alexander Hammond, Nancy Read, et al.
Plos One|June 30, 2012
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancerMalek B Hannouf, Chander Sehgal, Jeffrey Q Cao, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Journal of General Internal Medicine|July 18, 2014
Application of a policy framework for the public funding of drugs for rare diseasesEric Winquist, Doug Coyle, Joe T R Clarke, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2022
Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature reviewHugh Andrew Jinwook Kim, Anthony Charles Nichols, Ramanamurthy Rachakonda, et al.
Investigational New Drugs|September 20, 2006
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortiaGonzalo Gomez-Abuin, Eric Winquist, Walter M Stadler, et al.
Pageof 24

Showing results (91-100 of 234) with videos related to

Sort By:
Pageof 24
Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.
Journal of Oncology Practice|September 4, 2012
Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agentsMatthew A Weir, Tara Gomes, Eric Winquist, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 27, 2008
Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysisScott C Morgan, Tricia S Waldron, Libni Eapen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 10, 2010
High-intensity focused ultrasound for prostate cancer: a practice guidelineHimu Lukka, Tricia Waldron, Joseph Chin, et al.
Journal of Medical Imaging and Radiation Oncology|October 15, 2013
Can radiological changes in lymph node volume during treatment predict success of radiation therapy in patients with locally advanced head and neck squamous cell carcinoma?Sanju Mishra, Alexander Hammond, Nancy Read, et al.
Plos One|June 30, 2012
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancerMalek B Hannouf, Chander Sehgal, Jeffrey Q Cao, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Journal of General Internal Medicine|July 18, 2014
Application of a policy framework for the public funding of drugs for rare diseasesEric Winquist, Doug Coyle, Joe T R Clarke, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2022
Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature reviewHugh Andrew Jinwook Kim, Anthony Charles Nichols, Ramanamurthy Rachakonda, et al.
Investigational New Drugs|September 20, 2006
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortiaGonzalo Gomez-Abuin, Eric Winquist, Walter M Stadler, et al.
Pageof 24